Get the Stockscreener App
14.28
18.86%
-3.32
After Hours:
14.27
-0.010
-0.07%
Cadrenal Therapeutics Inc stock is traded at $14.28, with a volume of 152.00K.
It is down -18.86% in the last 24 hours and up +19.00% over the past month.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
See More
Previous Close:
$17.60
Open:
$17.73
24h Volume:
152.00K
Relative Volume:
2.98
Market Cap:
$22.08M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-20.37
EPS:
-0.7012
Net Cash Flow:
$-3.95M
1W Performance:
-5.37%
1M Performance:
+19.00%
6M Performance:
+94.09%
1Y Performance:
+121.40%
1-Day Range:
$14.00
$17.80
1-Week Range:
$14.00
$18.00
52-Week Range:
$5.40
$32.55
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance
(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin - TipRanks
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - PR Newswire
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - PR Newswire
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2% - MarketBeat
Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) - MarketBeat
Long Term Trading Analysis for (CVKD) - Stock Traders Daily
Jacksonville stocks rise as market hits record highs - Jacksonville Daily Record
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8% - MarketBeat
Cadrenal Therapeutics Inc (CVKD-Q) QuotePress Release - The Globe and Mail
Where are the Opportunities in (CVKD) - Stock Traders Daily
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy - TipRanks
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference - Kilgore News Herald
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Forecasted to Earn Q3 2024 Earnings of ($2.18) Per Share - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Trading Down 4.1% - Defense World
WATCH LIVE: Fed Chair Jerome Powell speaks after a 50bp interest rate cut - Investing.com
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data - MSN
Cadrenal Therapeutics (CVKD) Stock Rallies In After-Market Trading Ahead Of Regulatory Meeting - Stocks Telegraph
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - MarketBeat
Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland - MSN
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Cadrenal Therapeutics regains Nasdaq compliance - Investing.com India
Cadrenal gears up for FDA talks on heart drug trial - Investing.com India
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients - PR Newswire
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients - PR Newswire
Upcoming Stock Splits This Week (August 19 to August 23) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested - MSN
Cadrenal announces 1-for-15 reverse stock split By Investing.com - Investing.com Australia
Cadrenal announces 1-for-15 reverse stock split - Investing.com
Cadrenal Therapeutics Inc: Analyzing CVKD Stock Trends - The InvestChronicle
CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cadrenal Therapeutics to Present at Upcoming Investor Conferences - Longview News-Journal
Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now - Yahoo Finance
Q3 2024 Earnings Estimate for Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Issued By HC Wainwright - Defense World
10 Best New Penny Stocks To Buy Now - Insider Monkey
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update - PR Newswire
CVKD: Cadrenal Therapeutics and Abbott Collaborate on Novel Anticoagulant for LVAD Patients - Zacks Small Cap Research
Cadrenal Therapeutics Inc (CVKD) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
CVKD’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Cadrenal Therapeutics Partners with Abbott on Cardiac Trial - TipRanks
Ponte Vedra-based Cadrenal Therapeutics in talks for partnership with Abbott - Jacksonville Business Journal
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs - PR Newswire
Cadrenal Therapeutics announces stock incentive plan expansion - Investing.com
Cadrenal Therapeutics announces stock incentive plan expansion By Investing.com - Investing.com Australia
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.11%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):